Skip to main content

Table 1 Cohort description

From: SAR1a promoter polymorphisms are not associated with fetal hemoglobin in patients with sickle cell disease from Cameroon

Variables

 

Mean ± SD

Value range

Number of observations

Age (years)

 

17.9 ± 10.6

5–57

484

Haematological indices

RBC (1012/l)

2.8 ± 0.7

1.2–5.5

484

Hb (g/dl)

7.8 ± 1.6

4.0–13.5

484

MCV(fl)

84.6 ± 10.0

61–112

484

MCHC (g/dl)

34.2 ± 3.8

22.3–54.0

484

WBC (109/l)

14.7 ± 6.4

3.5–48.8

484

Lymphocytes (109/l)

6.1 ± 3.3

0.87–20.4

484

Monocytes (109/l)

1.7 ± 1.4

0.1–10.9

484

Platelets (109/l)

371.5 ± 131.6

108–827

484

HbA2 (%)

3.6 ± 2.1

0.1–18.2

484

HbF (%)

10.1 ± 8.5

0–37.4

484

Clinical events

Vaso-occlusive crisis (No./year)

2.8 ± 3.3

0–40

484

Consultations (No./year)

3.0 ± 3.9

0–24

484

Hospitalisation (No./year)

1.4 ± 2.5

0–30

484

Overt stroke

4.5%

 

22/484

3.7del α-globin gene genotypes

αα/αα

62.9%

 

304/484a

αα/α3.7

28.5%

 

138/484a

α3.7/α3.7

8.6%

 

42/484a

β-globin gene haplotypes

Benin/Benin

50.2%

 

243/484a

Benin/Cameroon

21.7%

 

105/484a

Benin/Atypical

4.1%

 

20/484a

Cameroon/Cameroon

4.1%

 

20/484a

  1. RBC red blood cells, Hb hemoglobin, MCV mean corpuscular volume, MCHC mean corpuscular haemoglobin concentration, WBC white blood cells, HbA2 hemoglobin α2, HbF hemoglobin F
  2. aNumber of individuals and not alleles